Industry Presses EU To Agree Medicines Deal With UK
Pharma Firms ‘Extremely Concerned’ Over Lack Of Progress In Talks
Executive Summary
A letter addressed to EU leaders has urged them to prioritize the preservation of supply chains and access to medicines for patients in both the UK and the EU as worries grow over the sluggish pace of talks on a trade deal.
You may also be interested in...
EU Issues Post-Brexit Clinical Trial Warning
The UK’s departure from the EU imposes a number of requirements on sponsors running EU trials, but it seems that many have still not taken steps to fall into line.
UK's Post-Brexit Medicine Plans Under Pressure
UK proposals for limited cooperation with the EU in medicines regulation, including the recognition of certificates and inspections, are one glimmer of light in an otherwise uncertain post-Brexit regulatory scenario for the UK. But time pressures and political spats over the future relationship could throw the whole enterprise into doubt.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.